Have you ever watched the broader market get completely hammered while a couple of your positions quietly keep climbing? That exact scenario played out on Thursday, and it felt pretty satisfying to act on it. While tech and data-center related names were getting slaughtered, two growth healthcare holdings continued to deliver, giving us the perfect window to lock in some serious profits without abandoning the thesis that originally got us in.
Why Trimming Winners Still Feels Right Even When They Keep Working
I’ve always believed that the hardest part of investing isn’t finding good companies. It’s knowing when to take a little off the table so the rest of the position can run with less emotional pressure. On Thursday the market offered a textbook example. Broad indices were deep in the red, yet Cardinal Health and Eli Lilly both held up remarkably well. In fact Cardinal Health was one of the better performers in the entire S&P 500 that day after delivering a strong earnings beat and raising its full-year outlook.
That kind of relative strength doesn’t happen by accident. It usually means the underlying business is doing something right that the market is only beginning to appreciate. Still, after a more than 20 percent rally since the end of September for both names, the prudent move felt clear: peel some shares, realize the gains, and keep a meaningful core position for the longer road ahead.
Cardinal Health’s Quiet Climb And The Decision To Sell
Cardinal Health has been a steady compounder in the portfolio all year. The stock purchased back in March of this year is now up roughly 20 percent. When a company reports better-than-expected numbers and lifts guidance, the shares often gap higher and then keep grinding. That’s exactly what happened. Rather than sit and hope the move continues indefinitely, we sold 50 shares near 273 dollars. The remaining 375 shares still represent about 2.75 percent of the overall portfolio, down only slightly from the previous 3 percent weighting.
In my experience, these modest trims do two useful things. First they free up cash that can be redeployed when genuine opportunities appear. Second they reduce the emotional weight of any single position. Healthcare distributors aren’t the flashiest stories on the tape, yet they tend to keep delivering when more speculative areas of the market stumble. That resilience is precisely why the position still deserves a solid allocation even after booking the gain.
Sometimes the smartest trade is the one that feels a little early. Waiting for perfection often means giving back a meaningful portion of the advance.
The post-earnings strength extended what had already been a strong run. Selling a slice into that strength is consistent with a broader approach of harvesting gains rather than chasing prices higher. It’s not about predicting the top. It’s about acknowledging that a 20 percent move in a relatively short window already delivered what many investors hope to capture over an entire year.
Eli Lilly’s Remarkable Multi-Year Run And Another Round Of Profit Taking
Eli Lilly tells an even more dramatic story. Shares bought in February 2022 have produced a gain north of 500 percent. Let that sink in for a moment. Half a decade of patience turned a growth healthcare holding into one of the biggest contributors to overall performance. On Thursday the stock was modestly higher while everything around it was melting. The recent fantastic beat-and-raise from last week has clearly been rewarded by the market.
We sold just 10 shares near 1,420 dollars. The remaining 70 shares still make up about 2.6 percent of the portfolio, a small reduction from the prior 3 percent. Keeping the bulk of the position intact feels important. The fundamental drivers that produced those outsized returns haven’t disappeared overnight. At the same time, locking in part of a 500 percent winner creates a psychological buffer. Future volatility becomes easier to sit through when some of the original capital and a large portion of the profits are already secured.
I’ve found that the best long-term holdings often become the hardest ones to trim. Emotion wants to let them ride forever. Discipline says a portion of every big winner belongs in the realized-gains column. That tension is healthy. It forces regular re-evaluation of position size relative to conviction and portfolio risk.
Healthcare’s Role As A Diversifier When Tech Gets Hit
One of the quieter themes this year has been the deliberate effort to own growth healthcare names as a counterweight to the dominant data-center and artificial-intelligence narrative. That decision looked smart on Thursday. While anything remotely tied to heavy computing infrastructure got punished, the two healthcare positions held firm or advanced. Diversification isn’t just a buzzword when it actually cushions the portfolio on ugly days.
The broader market’s rejection of certain high-flying themes creates space for other sectors to shine. Healthcare has the dual advantage of secular growth drivers and relatively defensive characteristics. Companies that improve patient outcomes, expand access, or deliver better therapies tend to keep working through economic noise. Cardinal Health’s distribution network and Eli Lilly’s pipeline both sit inside that larger structural tailwind.
Still, no sector is immune forever. Taking some profits after a sharp multi-week advance is simply risk management. The remaining positions continue to provide the desired diversification while the cash raised sits ready for the next idea that meets the same high bar.
The Practical Mechanics Of The Trades
Both sales were executed with the same underlying logic: reduce weight modestly, crystallize meaningful gains, and leave the core thesis intact. For Cardinal Health the realized gain sits at about 20 percent on the March purchase. For Eli Lilly the number is far larger, reflecting the multi-year holding period. Neither trade was designed to exit the names. Both were designed to keep the portfolio balanced.
- Cardinal Health: sold 50 shares near 273, retaining 375 shares at roughly 2.75 percent of portfolio
- Eli Lilly: sold 10 shares near 1,420, retaining 70 shares at roughly 2.6 percent of portfolio
- Both names still viewed as long-term growth holdings inside the healthcare allocation
- Cash raised becomes available for future opportunities without forcing immediate redeployment
Position sizing after the trims remains intentional. Neither name is allowed to dominate the portfolio, yet both still carry enough weight to matter if the positive fundamental stories continue. That balance between conviction and prudence is something I try to revisit regularly.
Lessons From Letting Winners Work While Still Harvesting
There’s an old saying that nobody ever went broke taking profits. Like most market clichés it contains a useful core of truth. The danger, of course, is taking profits so early and so often that the real multi-baggers never get the chance to compound. The approach used here tries to split the difference. Keep a core, sell a slice, and stay open to adding back later if the story improves further or the price becomes more attractive again.
In my own experience the biggest regret usually isn’t the profit that was left on the table after a trim. It’s the oversized position that later gave back a large portion of gains because no discipline was applied along the way. Thursday’s action felt like a clean application of that lesson. The market was offering liquidity in names that had already delivered, and we took it.
Perhaps the most interesting aspect is how calm the process felt. When a position has already produced a 20 percent or 500 percent return, the decision to sell a portion stops feeling like a high-stakes call. It starts feeling like ordinary portfolio hygiene. That emotional shift is one of the quiet rewards of sticking with high-quality compounders for long stretches.
Looking Ahead Without Forcing The Next Move
Cash raised from these sales doesn’t need to be put to work tomorrow. Sitting with a bit more dry powder after a strong run in selected names is perfectly acceptable. The market will eventually present new opportunities, whether in healthcare or elsewhere. Until then the remaining Cardinal Health and Eli Lilly shares continue to offer exposure to businesses that have already proven they can deliver.
I’m still constructive on the broader growth-healthcare theme. The structural demand for better therapies, more efficient distribution, and improved patient outcomes isn’t going away. At the same time, valuations and recent price action deserve respect. Trimming into strength is one practical way to stay long the theme while managing risk.
Future earnings reports, pipeline updates, and broader market sentiment will all influence how these positions evolve. The important point is that the portfolio now holds realized gains, a slightly smaller but still meaningful allocation, and greater flexibility. That combination feels more robust than simply riding every advance without adjustment.
A Broader Perspective On Profit Taking In Volatile Markets
Thursday’s session offered a useful reminder that not every day needs to be about buying the dip. Sometimes the higher-quality move is selling the strength while others are forced to liquidate weaker holdings. Relative performance matters. When a couple of names can rise or hold steady while the rest of the market falls hard, the message is usually constructive for those specific businesses.
Of course no single day defines a long-term investment case. Cardinal Health’s raised guidance and Eli Lilly’s recent beat both point to underlying momentum that extends well beyond one session. The decision to take profits simply acknowledges that momentum has already been recognized by the market and that some of the resulting gains belong in the bank.
I’ve watched too many investors hold concentrated winners until the story eventually turns. The emotional attachment grows with the gains, and discipline fades. Systematic, modest trims help interrupt that pattern. They keep the focus on process rather than any single price target.
How These Moves Fit Into Overall Portfolio Construction
Every position ultimately has to earn its place relative to the rest of the holdings. After the sales, both Cardinal Health and Eli Lilly still sit at meaningful but not dominant weights. That feels appropriate given the combination of growth potential and the gains already realized. The healthcare allocation as a whole continues to serve its diversification purpose against the more volatile technology and growth-oriented segments of the market.
Cash generated doesn’t sit idle forever. It simply waits for the next idea that offers a similar balance of quality, growth, and reasonable valuation. Patience after a profitable trim is often underappreciated. The urge to redeploy immediately can lead to lower-quality decisions. Better to wait for clarity.
In the end the Thursday trades were small in size yet large in principle. They reinforced a consistent approach: own high-quality growth businesses, let them compound, and periodically harvest a portion of the gains so the portfolio stays balanced and flexible. That process doesn’t guarantee future results, but it does create a framework that has worked across different market environments.
Final Thoughts On Staying Disciplined When Markets Turn Ugly
Ugly market days test every investor’s process. The ones that hold up best are usually those that already contain a mix of defensive growth and opportunistic flexibility. Healthcare provided some of that defense on Thursday. Taking profits provided some of the flexibility. Together they turned a difficult session into a constructive one for the overall portfolio.
I’ll keep watching both names closely. The remaining shares still have work to do, and the fundamental stories remain intact. At the same time the realized gains already booked create breathing room. That combination of ownership and partial realization is, in my view, one of the cleaner ways to navigate markets that can turn from celebratory to punitive in a single session.
Whether the broader market finds its footing soon or continues to struggle, the approach stays the same. Own businesses you understand, size them thoughtfully, and never be afraid to bank a solid profit when the market hands it to you. Thursday offered exactly that opportunity in two names that have treated the portfolio well. Acting on it felt like the right call.
Markets will keep delivering both pain and opportunity. The goal is simply to capture more of the latter while limiting the damage from the former. Modest profit-taking in strong performers during weak overall sessions is one practical tool that helps move closer to that goal over time. The rest is patience, continuous learning, and a willingness to adjust when the evidence changes.
Looking back on the day, the most satisfying part wasn’t the percentage gains themselves. It was the sense that the process worked the way it was designed to work. Relative strength appeared, gains were available, and a portion of them was secured without abandoning the longer-term view. That kind of quiet consistency is what ultimately compounds into meaningful results across full market cycles.
So the next time the market delivers a rough session while a couple of your higher-quality holdings refuse to join the decline, consider whether a modest trim might be the higher-probability decision. It won’t always be. But on Thursday it certainly was, and the portfolio is a little stronger for having made the call.
